<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990509</url>
  </required_header>
  <id_info>
    <org_study_id>2009-173</org_study_id>
    <nct_id>NCT00990509</nct_id>
  </id_info>
  <brief_title>Albumin for Intracerebral Hemorrhage Intervention</brief_title>
  <acronym>ACHIEVE</acronym>
  <official_title>Albumin for Intracerebral Hemorrhage Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out what effects, good and bad, the medication Albumin
      has on subjects who have experienced a type of stroke known as an intracerebral hemorrhage
      (ICH). An ICH is when spontaneous bleeding into the brain occurs due to fragile blood
      vessels.

      This research is being done because currently there is no effective treatment for ICH.
      However, study investigators believe that Albumin, the medication being tested in this study,
      is safe and may help improve patient recovery from ICH over time.

      Subjects will be enrolled in the study for a total of 90 days. Following enrollment, subjects
      will be randomized to receive 3 daily injections of either Albumin or Placebo (liquid with no
      drug), and will receive 3 brain MRI scans (with and without contrast), as described below.

      All subjects will be monitored continuously through 96 hours after enrollment (5 days) in the
      Georgetown ICU. Blood tests and clinical evaluations of neurological status, consisting of
      questions about subjects' functional abilities and medical history, will occur in the
      Georgetown ICU once every 24 hours through post-enrollment Day 5. Additionally, subjects will
      receive daily chest x-rays, and daily EKGs (exams that monitor how your heart is doing by
      placing electrodes, or small monitors, on your skin in specific locations).

      Similar clinical evaluations will occur at Day 30 and Day 90. Should subjects be discharged
      at these time points, day 30 assessments will occur over the phone, and day 90 assessments
      will occur in-person at Georgetown University Medical Center.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We aim to determine the safety and explore the efficacy of human albumin as a neuroprotective
      (or cytoprotective) agent for the treatment of acute primary supratentorial ICH. Albumin
      therapy has been shown to be cytoprotective in animal studies of both ischemic stroke and
      intracerebral hemorrhage, and in a phase II human study in ischemic stroke.

      To date no acute intervention (beyond supportive medical care) has been identified to improve
      outcomes in patients with primary ICH. Neuronal injury from a primary ICH is due not only to
      the space occupying effects of the hemorrhage but also due to the development of edema and
      toxicity from blood breakdown products in the subacute phase. Cytoprotective strategies
      targeted to limit blood brain barrier (BBB) breakdown and edema formation hold promise as
      treatment strategies to limit this injury.

      A number of MR imaging outcome markers demonstrating a potential neuroprotective effect
      include measures of hematoma volume, perihematomal edema, and blood brain barrier disruption.
      The term &quot;hyperintense acute injury marker&quot; (HARM) has been proposed to describe the
      radiologic finding of hyperintense signal within the cerebrospinal fluid spaces visualized on
      post-contrast fluid attenuated inversion recovery (FLAIR) MRI in patients with acute ischemic
      stroke. HARM has the potential to serve as a marker of blood brain barrier disruption in
      patients with primary ICH. The current study will involve serial MR imaging in ICH patients
      randomized to placebo vs. albumin to assess whether there are differences in the frequency of
      HARM and perihematomal edema in the albumin treated patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment was stopped due to low recruitment and the PI's move to a different institution.
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Hyperintense Acute injuRy Marker (HARM)</measure>
    <time_frame>Day 5 MRI</time_frame>
    <description>Hyperintense Acute injuRy Marker (HARM) characterizes the frequency and severity of blood brain barrier disruption. Mean HARM is assessed on the post-contrast study using a previously developed 5 point scale (0 to 5).). A score of 0 indicates no HARM, whereas a score of 5 indicates diffuse and generalized HARM. 11 of 14 participants received a Day 5 MRI. HARM reads could only be performed on 4 of the 7 placebo subjects due to insufficient sequences or presence of subarachnoid blood. Mean HARM score is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Safety of Albumin Administration in Primary ICH</measure>
    <time_frame>Through Day 90 following enrollment</time_frame>
    <description>Serious adverse events. Specific safety outcomes assessed: frank pulmonary edema as visualized on chest X-Ray, congestive heart failure, neurological deterioration (4-point worsening on NIHSS), death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Intracerebral Hemorrhage (ICH) Volume</measure>
    <time_frame>Day 5 MRI</time_frame>
    <description>11 of 14 participants received a Day 5 MRI. Mean ICH volume based on 11 participants is presented.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <description>Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.</description>
    <arm_group_label>Albumin</arm_group_label>
    <other_name>BUMINATE 25%, Albumin (Human)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Brain MRI with and without contrast</intervention_name>
    <description>All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.
MRIs will be with and without contrast will be performed at:
Baseline
48 hours after enrollment(approximately Day 3)
96 hours after drug treatment begins (approximately Day 5)</description>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>1.5T Siemens Symphony MRI.</other_name>
    <other_name>3T Siemens Verio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary supratentorial ICH

          -  &lt; 48 hours from symptom onset

          -  Age &gt;18

          -  Signed informed consent obtained from the patient or patient's legally authorized
             representative

        Exclusion Criteria:

          -  ICH volume &lt; 5 cc

          -  Glasgow Coma Scale &lt; 6

          -  Surgical evacuation anticipated

          -  Pre-existing medical, neurological or psychiatric disease that would confound the
             neurological, functional, or imaging evaluations

          -  Pregnancy or breastfeeding

          -  Hemodynamic instability (SBP &lt; 100 mmHg, &gt; 200 mmHg)

          -  Current participation in another experimental treatment protocol

          -  Renal impairment with GFR &lt; 30 or Creatinine &gt; 2.0

          -  History of or known allergy to albumin

          -  History of or known severe allergy to rubber latex

          -  Episode/exacerbation of congestive heart failure (CHF) from any cause in the last 6
             months. (An episode of congestive heart failure is any heart failure that required a
             change in medication, diet or hospitalization)

          -  Acute myocardial infarction in the last 6 months

          -  Elevated serum troponin level on admission &gt; 0.1 mcg/L

          -  Known valvular heart disease with CHF in the last 6 months

          -  Known (or in the investigator's judgment) existence of severe aortic stenosis or
             mitral stenosis

          -  Cardiac surgery involving thoracotomy (e.g., coronary artery bypass graft (CABG),
             valve replacement surgery) in the last 6 months

          -  Suspicion of aortic dissection on admission

          -  Acute arrhythmia (including any tachy- or bradycardia) with hemodynamic instability on
             admission (systolic blood pressure &lt; 100 mmHg).

          -  Findings on physical examination of any of the following: (1) jugular venous
             distention (JVP &gt; 4 cm above the sternal angle); (2) 3rd heart sound; (3) resting
             tachycardia (heart rate &gt; 100/min) attributable to congestive heart failure; (4)
             abnormal hepatojugular reflux; (5) lower extremity pitting edema attributable to
             congestive heart failure or without apparent cause; (6) bilateral rales; and/or (7) if
             a chest x-ray is performed, definite evidence of pulmonary edema, bilateral pleural
             effusion, or pulmonary vascular redistribution.

          -  Current acute or chronic lung disease requiring supplemental chronic or intermittent
             oxygen therapy.

          -  Prosthetic heart valves

          -  Contraindication to MRI (metal implant, etc.)

          -  Documented left ventricular ejection fraction &lt; 35%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chelsea Kidwell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2009</study_first_submitted>
  <study_first_submitted_qc>October 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2009</study_first_posted>
  <results_first_submitted>July 22, 2014</results_first_submitted>
  <results_first_submitted_qc>August 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 29, 2014</results_first_posted>
  <last_update_submitted>August 19, 2014</last_update_submitted>
  <last_update_submitted_qc>August 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Georgetown University</investigator_affiliation>
    <investigator_full_name>Chelsea Kidwell, M.D.</investigator_full_name>
    <investigator_title>Professor of Neurology; Medical Director, Georgetown University Stroke Center</investigator_title>
  </responsible_party>
  <keyword>Primary ICH</keyword>
  <keyword>Albumin</keyword>
  <keyword>MRI</keyword>
  <keyword>Neuroimaging outcome</keyword>
  <keyword>Placebo-controlled</keyword>
  <keyword>Phase II</keyword>
  <keyword>Blinded</keyword>
  <keyword>Safety</keyword>
  <keyword>Acute ICH</keyword>
  <keyword>ICH</keyword>
  <keyword>Primary acute (&lt; 48 hours) supratentorial ICH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Albumin</title>
          <description>Albumin: Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.
MRIs will be with and without contrast will be performed at:
Baseline
48 hours after enrollment(approximately Day 3)
96 hours after drug treatment begins (approximately Day 5)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.
MRIs will be with and without contrast will be performed at:
Baseline
48 hours after enrollment(approximately Day 3)
96 hours after drug treatment begins (approximately Day 5)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Albumin</title>
          <description>Albumin: Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.
MRIs will be with and without contrast will be performed at:
Baseline
48 hours after enrollment(approximately Day 3)
96 hours after drug treatment begins (approximately Day 5)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.
MRIs will be with and without contrast will be performed at:
Baseline
48 hours after enrollment(approximately Day 3)
96 hours after drug treatment begins (approximately Day 5)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.6" lower_limit="41" upper_limit="82"/>
                    <measurement group_id="B2" value="58.1" lower_limit="41" upper_limit="76"/>
                    <measurement group_id="B3" value="59.7" lower_limit="41" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Hyperintense Acute injuRy Marker (HARM)</title>
        <description>Hyperintense Acute injuRy Marker (HARM) characterizes the frequency and severity of blood brain barrier disruption. Mean HARM is assessed on the post-contrast study using a previously developed 5 point scale (0 to 5).). A score of 0 indicates no HARM, whereas a score of 5 indicates diffuse and generalized HARM. 11 of 14 participants received a Day 5 MRI. HARM reads could only be performed on 4 of the 7 placebo subjects due to insufficient sequences or presence of subarachnoid blood. Mean HARM score is presented.</description>
        <time_frame>Day 5 MRI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Albumin: Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.
MRIs will be with and without contrast will be performed at:
Baseline
48 hours after enrollment(approximately Day 3)
96 hours after drug treatment begins (approximately Day 5)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.
MRIs will be with and without contrast will be performed at:
Baseline
48 hours after enrollment(approximately Day 3)
96 hours after drug treatment begins (approximately Day 5)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Hyperintense Acute injuRy Marker (HARM)</title>
          <description>Hyperintense Acute injuRy Marker (HARM) characterizes the frequency and severity of blood brain barrier disruption. Mean HARM is assessed on the post-contrast study using a previously developed 5 point scale (0 to 5).). A score of 0 indicates no HARM, whereas a score of 5 indicates diffuse and generalized HARM. 11 of 14 participants received a Day 5 MRI. HARM reads could only be performed on 4 of the 7 placebo subjects due to insufficient sequences or presence of subarachnoid blood. Mean HARM score is presented.</description>
          <units>points</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Insufficient number of patients with outcome measure available for meaningful analysis as trial was stopped early. Analysis of a small number of observations would be misleading.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Safety of Albumin Administration in Primary ICH</title>
        <description>Serious adverse events. Specific safety outcomes assessed: frank pulmonary edema as visualized on chest X-Ray, congestive heart failure, neurological deterioration (4-point worsening on NIHSS), death</description>
        <time_frame>Through Day 90 following enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Albumin: Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.
MRIs will be with and without contrast will be performed at:
Baseline
48 hours after enrollment(approximately Day 3)
96 hours after drug treatment begins (approximately Day 5)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.
MRIs will be with and without contrast will be performed at:
Baseline
48 hours after enrollment(approximately Day 3)
96 hours after drug treatment begins (approximately Day 5)</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Safety of Albumin Administration in Primary ICH</title>
          <description>Serious adverse events. Specific safety outcomes assessed: frank pulmonary edema as visualized on chest X-Ray, congestive heart failure, neurological deterioration (4-point worsening on NIHSS), death</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Edema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congestive Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurological Deterioration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Intracerebral Hemorrhage (ICH) Volume</title>
        <description>11 of 14 participants received a Day 5 MRI. Mean ICH volume based on 11 participants is presented.</description>
        <time_frame>Day 5 MRI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Albumin</title>
            <description>Albumin: Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.
MRIs will be with and without contrast will be performed at:
Baseline
48 hours after enrollment(approximately Day 3)
96 hours after drug treatment begins (approximately Day 5)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.
MRIs will be with and without contrast will be performed at:
Baseline
48 hours after enrollment(approximately Day 3)
96 hours after drug treatment begins (approximately Day 5)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Intracerebral Hemorrhage (ICH) Volume</title>
          <description>11 of 14 participants received a Day 5 MRI. Mean ICH volume based on 11 participants is presented.</description>
          <units>cc</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" spread="47.9"/>
                    <measurement group_id="O2" value="39.2" spread="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 Days</time_frame>
      <desc>We did not collect non-serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Albumin</title>
          <description>Albumin: Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.
MRIs will be with and without contrast will be performed at:
Baseline
48 hours after enrollment(approximately Day 3)
96 hours after drug treatment begins (approximately Day 5)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment
Brain MRI with and without contrast: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.
MRIs will be with and without contrast will be performed at:
Baseline
48 hours after enrollment(approximately Day 3)
96 hours after drug treatment begins (approximately Day 5)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic Deterioration</sub_title>
                <description>The single event of neurologic deterioration documented in this study resulted in death due to respiratory failure and was adjudicated to be unrelated to the study interventions.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There was an insufficient number of subjects in each treatment arm to allow for a meaningful analysis of the effects of albumin on HARM status (blood brain barrier disruption).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chelsea Kidwell, MD</name_or_title>
      <organization>University of Arizona</organization>
      <phone>(520) 626-7159</phone>
      <email>ckidwell@neurology.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

